Abstracted Scientific Content

Published in:
Volume 3 / Year 2014 / Issue 1

Biosimilarity of anticancer monoclonal antibodies in the clinic

Page: 39

The European Medicines Agency recommends the use of pharmacodynamics (PD) markers when establishing biosimilarity, but no such biomarkers are known for the clinical efficacy of bevacizumab (Avastin). For this reason,… Read More »

Go Back Print